Fractyl Health Inc GUTS
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-02-02 |
| Shares Out. | 158,650,000 |
| Website | fractyl.com/ ↗ |
| Phone | 17819028800 |
| Employees | 73 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$25.5M |
| Free Cash Flow | -$82.4M |
| Total Assets | $82.0M |
| Total Liabilities | $83.6M |
| Equity | -$1.7M |
About Fractyl Health Inc
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
Fractyl Health Inc is a publicly traded company under the ticker symbol GUTS on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-09-01)